trending Market Intelligence /marketintelligence/en/news-insights/trending/yUNzSptGOt-b364vgAcwNw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Corvus Pharma cancer treatment shows anti-tumor activity

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Corvus Pharma cancer treatment shows anti-tumor activity

Corvus Pharmaceuticals Inc. said its lead product CPI-444, as a single agent and in combination with atezolizumab, showed anti-tumor activity, based on interim results from the renal cell carcinoma, or RCC, and non-small cell lung cancer, or NSCLC, expansion cohorts in an ongoing phase 1/1b study.

The treatment demonstrated anti-tumor activity in patients resistant or refractory to prior treatment with anti-programmed death-ligand 1, or PD-(L)1, antibodies and patients with PD-L1 negative tumors.

Among 22 evaluable RCC patients, best tumor response data showed two confirmed partial responses. In this group, 16 patients achieved stable disease, including six who experienced minor regressions.

Best tumor response data for NSCLC patients showed two partial responses out of 34 evaluable patients. In this group, 22 patients achieved stable disease, including four who experienced minor regressions.

Corvus said CPI-444 remains well tolerated, with observed adverse events similar to previous reports.

CPI-444 is a checkpoint inhibitor that obstructs adenosine in the tumor microenvironment. Atezolizumab is a monoclonal antibody targeting and binding to PD-L1. Atezolizumab is also known as Tecentriq, which is developed by Roche Holding Ltd. unit Genentech Inc.